Publications of Bozidar Novak
All genres
Journal Article (10)
1.
Journal Article
172, pp. 221 - 228 (2024)
Prefrontal cortical synaptoproteome profile combined with machine learning predicts resilience towards chronic social isolation in rats. JOURNAL OF PSYCHIATRIC RESEARCH 2.
Journal Article
282, 104925 (2023)
Chronic fluoxetine treatment in socially-isolated rats modulates the prefrontal cortex synaptoproteome. JOURNAL OF PROTEOMICS 3.
Journal Article
501, pp. 52 - 71 (2022)
Chronic Fluoxetine Treatment of Socially Isolated Rats Modulates Prefrontal Cortex Proteome. NEUROSCIENCE 4.
Journal Article
110 (14), pp. 2283 - 2298.e9 (2022)
Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2. NEURON 5.
Journal Article
51, pp. 20 - 32 (2021)
MMP9 mRNA is a potential diagnostic and treatment monitoring marker for PTSD: Evidence from mice and humans. EUROPEAN NEUROPSYCHOPHARMACOLOGY 6.
Journal Article
15, 100401 (2021)
Analysis of the cerebellar molecular stress response led to first evidence of a role for FKBP51 in brain FKBP52 expression in mice and humans. NEUROBIOLOGY OF STRESS 7.
Journal Article
129, 105242 (2021)
Oxytocin receptor is a potential biomarker of the hyporesponsive HPA axis subtype of PTSD and might be modulated by HPA axis reactivity traits in humans and mice. PSYCHONEUROENDOCRINOLOGY 8.
Journal Article
129, pp. 8 - 14 (2020)
Paroxetine binding and activation of phosphofructokinase implicates energy metabolism in antidepressant mode of action. JOURNAL OF PSYCHIATRIC RESEARCH 9.
Journal Article
15 (9), e1008358 (2019)
Multi-omics analysis identifies mitochondrial pathways associated with anxiety-related behavior. PLoS Genetics 10.
Journal Article
55, pp. 102 - 115 (2015)
Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD patients. PSYCHONEUROENDOCRINOLOGY Meeting Abstract (1)
11.
Meeting Abstract
63, p. E101 - E101. (2022)
GENOME-WIDE ANALYSIS IDENTIFIES SORCS3 AS A NOVEL SUSCEPTIBILITY LOCUS FOR PANIC DISORDER IN THE FINNGEN STUDY. In EUROPEAN NEUROPSYCHOPHARMACOLOGY,